Home > Press > Harris & Harris Group Invests in Ancora Pharmaceuticals
Harris & Harris Group, Inc., announced today that it has invested in Ancora Pharmaceuticals Inc., based in Medford, Massachusetts. Douglas W. Jamison, President and COO of Harris & Harris Group, has joined Ancora's Board of Directors.
Harris & Harris Group Invests in Ancora Pharmaceuticals
NEW YORK, NY | Posted on June 4th, 2007
Ancora Pharmaceuticals Inc. is dedicated to enabling synthetic carbohydrate-based product discovery and development utilizing its state-of-the-art carbohydrate synthesis capability, which is based on technology originally developed at the Massachusetts Institute of Technology (M.I.T.). The company is applying its synthesis technology both to internal drug development programs and strategic collaborations within the pharmaceutical and biotechnology sector.
About Harris & Harris Group, Inc.
Harris & Harris Group is a publicly traded venture capital company that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 33 initial private equity investments have been in tiny technology-enabled companies. The Company has 21,783,444 shares of common stock outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at http://www.TinyTechVC.com .
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Registration Statement on Form N-2 and Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc., undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website http://www.TinyTechVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.
For more information, please click here
Harris & Harris Group, Inc.
Douglas W. Jamison
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Arrowhead Issues Open Letter to Shareholders October 9th, 2014
PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014
Aspen Aerogels, Inc. to Present at Barclays CEO Energy-Power Conference August 27th, 2014
Harris & Harris Group Letter to Shareholders on Website August 19th, 2014
Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014
Nitrogen Doped Graphene Characterized by Iranian, Russian, German Scientists October 21st, 2014
Physicists build reversible laser tractor beam October 20th, 2014
Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014